Annals of Oncology 13:1749-1755, 2002
© 2002 European Society for Medical Oncology
Original Paper |
A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy
1 Departments of Gynaecology and Obstetrics, Charité Virchow University Hospital, Berlin; 2 Institute of Clinical Economics (ICE), Department of Trauma Surgery, Ernst–Moritz–Arndt University Greifswald, Greifswald; 3 Hospital of Hoyerswerda, Hoyerswerda; 4 Gynaecological Practice, Berlin; 5 Gynaecological Practice, Finsterwalde; 6 Oskar–Ziethen Hospital, Berlin; 7 Vivantes Friedrichshain Hospital, Berlin, Germany
Received 13 December 2001; revised 21 March 2002; accepted 10 April 2002
Background:
Second-line chemotherapy for patients with ovarian cancer who failed platinum and paclitaxel treatment remains a therapeutic challenge. We investigated the toxicity profile and therapeutic efficacy of a novel combination regimen, topotecan plus gemcitabine, in a clinical phase II study.
Patients and methods:
Women with relapsed epithelial ovarian cancer after platinum and paclitaxel treatment were eligible to participate in this trial. Topotecan was given at an initial dose of 0.5 mg/m2 daily (days 1–5), combined with gemcitabine 800 mg/m2 and 600 mg/m2 on days 1 and 8, respectively. Precluding good tolerability, this protocol facilitated subsequent dose increases of topotecan up to 1.0 mg/m2. The primary objective was to determine the dose-limiting toxicity, whereas secondary objectives comprised measurable and CA-125 response rates, disease-free and overall survival.
Results:
The twenty-one patients (median age 57 years, range 37–70 years) who were allocated to this trial received a total of 94 courses of chemotherapy. Median follow-up was 20.5 months. Topotecan dosage could be escalated to 0.75 mg/m2 in nine patients and 1 mg/m2 in another two patients. Dose reduction was not necessary in any case. There were no episodes of neutropenic fever, sepsis or chemotherapy-related fatalities. Only one patient developed CTC grade 4 leukopenia after the first treatment cycle, whereas three patients showed grade 3/4 anaemia. Five patients experienced thrombocytopenia grade 4 without clinical sequelae. Non-hematological toxicities were mild and rare. Eleven patients could be evaluated for clinical tumour response, with three complete, and four partial remissions. Two patients each had stable and progressive diseases. The median progression-free survival rate was 8.8 months [95% confidence interval (CI) 6.3–13.4 months]. The median overall survival rate was 21.1 months (95% CI 14.8–22.1 months).
Conclusions:
Topotecan combined with gemcitabine has a favourable toxicity profile and encouraging efficacy in patients with recurrent ovarian cancer.
Key words: combination chemotherapy, gemcitabine, ovarian malignancy, topotecan, toxicity
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. ITANI, K. HOSOKAWA, K. ITO, S. TAKEUCHI, T. TABATA, H. TSUBAMOTO, H. FUJITA, M. AKIYAMA, and S. ADACHI A Phase I/II Study of Docetaxel and Gemcitabine Combination for Chemotherapy-resistant Ovarian Cancer Anticancer Res, May 1, 2009; 29(5): 1521 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sehouli, D. Stengel, G. Oskay-Oezcelik, A. G. Zeimet, H. Sommer, P. Klare, M. Stauch, A. Paulenz, O. Camara, E. Keil, et al. Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group J. Clin. Oncol., July 1, 2008; 26(19): 3176 - 3182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Herzog Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression? Clin. Cancer Res., November 15, 2004; 10(22): 7439 - 7449. [Abstract] [Full Text] [PDF]
|
|